Stocks · News reference
HC Wainwright & Co. analyst Yi Chen maintains Biodesix (NASDAQ:BDSX) with a Buy and raises the price target from $26 to $27.
Reference Details
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
Keep reading
Biodesix, Inc. announced its participation in three upcoming investor conferences in September 2026. The company reported Q2 2026 revenue of $26.9 million, representing 34% growth, with an 82% gross margin. Biodesix maintained its FY 2026 revenue guidance of $108-114 million, reflecting 25% growth expectations.
Canaccord Genuity analyst Kyle Mikson maintains Biodesix (NASDAQ:BDSX) with a Buy and raises the price target from $27 to $35.
Biodesix (NASDAQ:BDSX) affirms FY2026 sales outlook from $108.000 million-$114.000 million to $108.000 million-$114.000 million vs $110.996 million estimate.